公开(公告)号：US20230113705A1

公开(公告)日：2023-04-13

申请号：US17904910

申请日：2021-02-26

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Ceinge Biotecnologie Avanzate SCARL ,  Institut Gustave Roussy ,  Sorbonne Université ,  Université Paris Cité ,  Assistance Publique-Hôpitaux de Paris (APHP)

发明人： Chiara MAIURI ,  Guido KROEMER ,  Jonathan POL ,  Francesco SALVATORE ,  Fatima DE PALMA ,  Valentina DEL MONACO

IPC分类号： C12Q1/6886

摘要： The present invention relates to methods and compositions for the care of breast cancer, from diagnosis to treatment management. The inventors show that LINC01087 downregulation contributes to a more aggressive phenotype of BC, and could represents a novel and promising specific biomarker for the diagnosis of triple-negative breast cancer. The inventors show that LINC01087 upregulation contributes to a less aggressive phenotype of BC, and could represents a novel and promising specific biomarker for the diagnosis of luminal BCs. The invention relates to a method comprising the steps of: i) determining the expression level of the long intergenic non-coding RNA 01087 (LINC01087) in a sample obtained from the subject, and ii) comparing the expression level determined at step i) with a predetermined reference value, wherein detecting difference between the expression level determined at step i) and the predetermined reference value is indicative of an aggressive TNBC or less aggressive luminal BCs.